




Essai Clinique

Généré le 02 mai 2024 à partir de

Titre	Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer
Protocole ID	CRC.9 (COBRA)
ClinicalTrials.gov ID	NCT04068103
Type(s) de cancer	Côlon et rectum
Phase	Phase II-III
Type étude	Clinique
Institution	CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL  HOPITAL DU SACRE-COEUR-DE-MONTREAL 5400 boul. Gouin Ouest, Montréal, QC, H4J1C5
Ville	
Investigateur principal	Dre Setareh Samimi
Coordonnateur	Marie-Anne Capobianco 514-338-2222 poste 3493
Statut	Fermé
But étude	This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery. ctDNA are circulating tumor cells that are shed by tumors into the blood. Finding ctDNA in the blood means that there is very likely some small amounts of cancer that remain after surgery. However, this cancer, if detected, cannot be found on other tests usually used to find cancer, as it is too small. Testing for ctDNA levels may help identify patients with colon cancer after surgery who do benefit, and those who do not benefit, from receiving chemotherapy.
Critères d'éligibilité	
Critères d'exclusion	